Pertuzumab biosimilar(SL Pharma/Combio)

帕妥珠单抗生物类似物（双鹭药业/康明百奥）

Report date: 2026/05/26 20:00:28

Base Information

Drug NamePertuzumab biosimilar(SL Pharma/Combio)
Drug Alias Name重组抗HER2结构域II人源化单克隆抗体
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerInflammatory Breast NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Sl Pharmaceutical Co LtdBeijing Kangming Bio New Drug Development Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Sl Pharmaceutical Co LtdBeijing Kangming Bio New Drug Development Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerInflammatory Breast NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A